# US 2004/0203044 A1 · Promoting cardiac cell differentiation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0203044 A1
- Document ID: US20040203044A1
- Status: Published application
- Kind: A1
- Application number: 10/822,496
- Filed: 2004-04-12
- Published: 2004-10-14
- Earliest claimed: 2003-04-10
- Assignees: Florid Atlantic University
- Inventors: Larry F. Lemanski; Chi Zhang
- Web page: https://patentgrep.com/patent/US20040203044A1

## CPC

- C07H 21/02: with ribosyl as saccharide radical
- C07K 14/47: from mammals
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Compositions and methods for inducing a cardiac muscle phenotype, such as rhythmic contraction and formation of myofibrils, in a cell are described. Disclosed are nucleic acids encoding myofibrillogenesis-inducing RNA (MIR) molecules, RNA molecules (MIR) and RNA-binding proteins that bind to MIR to induce myofibrillogenesis and vectors comprising these nucleic acids. Also included is a method of promoting cardiac muscle differentiation using these compositions.

## Claims

### Claim 1

A purified nucleic acid comprising a nucleotide sequence that encodes a myofibrillogeneis-inducing RNA (MIR) molecule having at least one functional activity of a native MIR molecule.

### Claim 2 (depends on 1)

The purified nucleic acid of claim 1, wherein said nucleotide sequence encodes an RNA molecule having a secondary structure that permits specific binding to at least one MIR-binding protein.

### Claim 3 (depends on 1)

The purified nucleic acid of claim 1, comprising a nucleotide sequence whose complement hybridizes under stringent hybridization conditions to the nucleotide sequence of at least one of SEQ ID NO:2 and SEQ ID NO:3.

### Claim 4 (depends on 1)

The purified nucleic acid of claim 1, wherein the nucleotide sequence comprises SEQ ID NO:1 and is greater than 166 nucleotides in length.

### Claim 5 (depends on 1)

The purified nucleic acid of claim 1, wherein the nucleotide sequence shares at least 75% sequence identity with SEQ ID NO:5.

### Claim 6 (depends on 1)

The purified nucleic acid sequence of claim 1, wherein the nucleotide sequence comprises SEQ ID NO:5.

### Claim 7 (depends on 1)

The purified nucleic acid of claim 1, wherein a portion of said nucleotide sequence that encodes a MIR molecule comprises a first polynucleotide sequence that shares sequence identity with a second polynucleotide sequence within the 5′ untranslated region of a second nucleic acid that encodes an RNA splicing factor.

### Claim 8 (depends on 7)

The purified nucleic acid of claim 7, wherein said RNA splicing factor is SmN.

### Claim 9 (depends on 8)

The purified nucleic acid of claim 8, wherein said first and said second polynucleotide sequences comprise the sequence of SEQ ID NO:6.

### Claim 10

A purified myofibrillogenesis-inducing RNA (MIR) molecule comprising a ribonucleic acid sequence is a complement of a deoxyribonucleic acid sequence that encodes a myofibrillogeneis-inducing RNA (MIR) molecule having at least one functional activity of a native MIR molecule, wherein said deoxyribonucleic acid sequence encodes a polyribonucleic acid that is between about 167 and about 620 nucleotides in length.

### Claim 11 (depends on 10)

The purified MIR molecule of claim 10, wherein said deoxyribonucleotide sequence comprises the sequence of SEQ ID NO:1.

### Claim 12 (depends on 10)

The purified MIR molecule of claim 10, wherein said deoxyribonucleotide sequence comprises the sequence of SEQ ID NO:5.

### Claim 13

A vector comprising a purified nucleic acid that encodes a myofibrillogeneis-inducing RNA (MIR) molecule having at least one functional activity of a native MIR molecule.

### Claim 14 (depends on 13)

The vector of claim 13, wherein the purified nucleic acid further encodes a MIR-binding protein.

### Claim 15

A method of inducing a cardiac muscle phenotype in a cell, said method comprising the steps of:
a) providing a cell comprising at least one MIR-binding protein; and
b) contacting said cell with at least one MIR molecule that specifically binds to said at least one MIR-binding protein, in an amount sufficient to induce a cardiac muscle phenotype in said cell.

### Claim 16 (depends on 15)

The method of claim 15, wherein said cardiac muscle phenotype comprises formation of myofibrils or rhythmic contraction of the cell.

### Claim 17 (depends on 15)

The method of claim 15, wherein said MIR-binding protein is selected from the group consisting of MIR-binding proteins having molecular weights of about 11-13 kDa and about 28-30 kDa.

### Claim 18 (depends on 15)

The method of claim 15, wherein said at least one MIR molecule is encoded by a nucleic acid comprising a sequence that is less than 166 nucleotides in length and shares at least 75% sequence identity with SEQ ID NO:1.

### Claim 19 (depends on 15)

The method of claim 15, wherein said at least one MIR molecule is encoded by a nucleic acid comprising a sequence that is at least 167 nucleotides in length and shares at least 75% sequence identity with SEQ ID NO:5.

### Claim 20 (depends on 15)

The method of claim 15, wherein said at least one MIR-binding protein is exogenously added to said cell.

### Claim 21 (depends on 15)

The method of claim 15, wherein said cell is a stem cell.

### Claim 22 (depends on 15)

The method of claim 15, wherein said step (b) comprises contacting said cell with a vector that comprises a nucleic acid that encodes said at least one MIR molecule.

### Claim 23 (depends on 21)

The method of claim 21, wherein said nucleic acid further comprises a nucleotide sequence that encodes a MIR-binding protein.

### Claim 24 (depends on 21)

The method of claim 21, wherein said cell is comprised within a heart.
